RxDoctor Payments Data

Stephen Rechenmacher, MD

Clinical Cardiac Electrophysiology · Vancouver, WANPI 1417273129

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 79.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $174 and has fallen 64.9% since, to $61 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in WA, where the typical reported total is $7,912.

$532in general payments, 2019–2025

Across 29 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$421
  • Biosense Webster, Inc.$68
  • Amgen$19
  • Medtronic$14
  • Regeneron Healthcare Solutions, Inc.$11

What the payments were for

  • Food & beverage$532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$532 in reported general payments places this provider in the 15th percentile of 68 clinical cardiac electrophysiology providers in Washington.

See all clinical cardiac electrophysiology providers in Washington

Medicare billing

Part B allowed, 2024
$168,435
Medicare patients
259
Services billed
914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$301,549
MultaqDronedarone Hcl11$21,935
XareltoRivaroxaban16$18,978
CorlanorIvabradine Hcl11$9,704
Metoprolol Succinate145$2,158
Mexiletine Hcl12$1,543
Diltiazem 24hr Er (Xr)Diltiazem Hcl22$1,363
Flecainide Acetate26$784
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$770
Dilt-XrDiltiazem Hcl18$561
SotalolSotalol Hcl18$490
Amiodarone Hcl34$449
Omeprazole29$444
Losartan Potassium42$425
Carvedilol36$356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenCorlanor$19$9,70411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 68 clinical cardiac electrophysiology providers in Washington.

Other clinical cardiac electrophysiology in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →